Beyond the diagnosis.

We focus on the complexities of cancer so you can focus on the care.

OncoHealth delivers digital health solutions that reduce the physical, mental, and financial toll of cancer for everyone involved.

With a cancer diagnosis, comes many questions

health coverage

What will be the impact on my quality of life?

health coverage

What are my treatment options?

health coverage

How much is this going to cost?

health coverage

How severe are the side-effects?

Better care drives better outcomes.

OncoHealth is dedicated to helping health plans, employers, providers, patients, and life science researchers navigate the physical, mental and financial complexities of cancer through technology enabled services and real-world data analytics.

See how we can support you

Rebecca's Story

Rebecca's Story

Rebecca, a 61-year-old grandmother and substitute teacher was diagnosed with a rare form of inflammatory breast cancer, underwent chemotherapy and a modified radical mastectomy. A month after her surgery, Rebecca developed multiple lesions below her mastectomy scar which turned out to be metastatic breast cancer to the skin.
Medical Moment of Truth

Medical Moment of Truth

Rebecca and her doctors faced a choice of between the molecularly targeted therapies Piqray or Ibrance, either in combination with letrozole. Her tumor’s next-generation sequencing biomarker data revealed a PIK3CA H1047R mutation, which suggested that Piqray could be an effective treatment. But Rebecca’s medical records described a history of poorly controlled diabetes, and Piqray is known to cause or worsen high blood sugar in many patients who take it.
Personalized Treatments

Personalized Treatments

Rebecca’s health plan was presented with a request for treatment with Piqray + letrozole at a 3-month cost of $54,828. Given that Piqray-based therapy has only been proven effective in the second-line setting, OncoHealth reviewed the data and found that a first-line treatment of Ibrance + letrozole could reduce the risk of death by 34%, avoid the risk of potentially life-threatening hyperglycemia, and result in a 3-month savings of $14,397.
Advancing Oncology Research

Advancing Oncology Research

Leveraging de-identified, real-world data from a cohort of patients like Rebecca, life sciences researchers were able to answer questions such as do certain cohorts have better outcomes with one drug versus another; what impact does a PIK3CA mutation have on treatment effectiveness, and why was one drug prescribed over another?
Oncology Expertise

Trusted for Our Oncology Expertise by

15

Health Plans

106

ASO Employers with over 250+ Employees

8K+

Providers

500K

People with Cancer

Stay Current

PRESS RELEASE

OncoHealth and Triple-S Salud of Puerto Rico Partner for Evidence-Based Cancer Treatment

Digital Health Company Now Handling Oncology Treatment Reviews for 100% of Medicare Advantage and Medicaid Members
January 11, 2022

READ MORE >

PRESS RELEASE

OncoHealth Continues Significant Revenue, Membership, Employee Growth and Innovation in Successful 2021

Company increased YOY revenue by 43%, delivered $120 million of financial impact to clients and added 1.2 million new members to its digital oncology platform
January 25, 2021

READ MORE >

WEBINAR

OncoHealth’s Quarterly Analysis of the FDA’s Recent Cancer Drug Approvals

December 16
2:00 PM EST

REGISTER >

PRESS RELEASE

OncoHealth’s Analysis of the FDA’s H2 2021 Drug Approval Activity Shows Largest Number of Oncology Accelerated Approval Withdrawals in 11 Years

Report also reveals a 35% increase in cancer indication approvals, and a 5x rise in pre- and postoperative approvals in the curative-intent setting
December 14, 2021

READ MORE >

FDA REPORT

OncoHealth FDA Oncology Drug Approvals Report

December 2021

DOWNLOAD THE REPORT >

PRESS RELEASE

Oncology Analytics Announces Rebrand to OncoHealth

New name comes on the heels of major growth period and reflects the company’s expanding digital health portfolio
September 20, 2021

READ MORE >

PRESS RELEASE

OncoHealth Announces Three C-Suite Promotions

Shay Hurst named Chief People Officer, Sara Zywicki named Chief Product Officer, Kathy Mosbaugh named Chief Customer Officer
December 20, 2021

READ MORE >

Subscribe To Our Newsletter

Join our monthly mailing list to receive the latest news and updates from OncoHealth.

You have Successfully Subscribed!

Subscribe To Our Newsletter

Join our monthly mailing list to receive the latest news and updates from OncoHealth.

You have Successfully Subscribed!